Our most advanced programs are synthetic lethal therapies for cancer. Genetic perturbations that fuel cancer growth can also introduce an over-dependence for the cancer cell on pathways and proteins that the normal, non-cancerous cell does not have. Anticancer Bioscience was founded by scientists that are experts in identifying and exploiting these cancer vulnerabilities. We have assembled a talented team of medicinal chemists and discovery scientists to tackle the opportunities we identify in the oncology space. It is our goal to advance safe, effective, and broad-spectrum targeted therapies for cancers that remain inaccessible or become refractory to existing therapy.
For more information about our pipeline of innovative drugs, the four technology platforms that fuel our discovery process, partnering, and employment opportunities available with ACB, please visit www.anticancerbio.com. ACB is an equal opportunity employer committed to developing a safe and prosperous work environment.
Overview
Funding Rounds 2
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
| Feb 8, 2021 | Funding round | $10M |
Mentions in press and media 6
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Oct 14, 2021 | Anticancer Bioscience : Welcomes New Investor into Seed Financing Round Bringing Total Raised to Over $31m to Advance Synthetic Lethality Approaches to Cancer Therapy | Anticancer Bioscience (ACB), pioneers in synthetic lethal approaches to precision oncology, announced today that it had secured an additional CNY 68.4 million (~USD 10.6 million) from new Chinese investors. The seed extension financing was ... |
| Feb 8, 2021 | Anticancer Bioscience Announces CNY63m (~USD10m) Financing to Advance its Synthetic Lethal Platform and Pre-clinical Oncology Pipeline | CHENGDU, China–(BUSINESS WIRE)–Feb 8, 2021– Anticancer Bioscience (ACB), pioneers in synthetic lethal approaches to precision oncology, announced today that having successfully closed an additional financing round, raising CNY63m (~USD10m),... |
| Feb 8, 2021 | Anticancer Bioscience Raises Approx. USD10M in Financing | Dr. Dun Yang, Founder, President and CEO, Anticancer Bioscience Anticancer Bioscience (ACB), a Chengdu, China-based pioneers in synthetic lethal approaches to precision oncology, closed an additional financing round, raising CNY63m (approx.... |
| Feb 8, 2021 | Anticancer Bioscience : Announces CNY63m (~USD10m) Financing to Advance its Synthetic Lethal Platform and Pre-clinical Oncology Pipeline | Anticancer Bioscience (ACB), pioneers in synthetic lethal approaches to precision oncology, announced today that having successfully closed an additional financing round, raising CNY63m (~USD10m), it has already achieved positive animal dat... |
| Jan 13, 2021 | Anticancer Bioscience Presenting at Biotech Showcase(TM) Digital 2021 Showcasing its Synthetic Lethal Precision Oncology Pipeline for the First Time | Chengdu, China--(Newsfile Corp. - January 13, 2021) - Anticancer Bioscience (ACB), pioneers in synthetic lethal approaches to precision oncology, announced today announced that it is participating in Biotech Showcase Digital 2021, for the f... |
Reviews 0
FAQ about Anticancer Bioscience
When was Anticancer Bioscience founded?
Anticancer Bioscience was founded in 2016.
How much funding has Anticancer Bioscience raised?
Anticancer Bioscience has raised $41M in total across 2 funding rounds.
What funding rounds has Anticancer Bioscience raised?
Parsers VC lists 2 funding rounds of Anticancer Bioscience, among them a funding round of $10M on Feb 8, 2021.
What has the press written about Anticancer Bioscience?
Parsers VC has collected 6 articles mentioning Anticancer Bioscience, among them “Anticancer Bioscience : Welcomes New Investor into Seed Financing Round Bringing Total Raised to Over $31m to Advance Synthetic Lethality Approaches to Cance...” (Oct 14, 2021) and “Anticancer Bioscience Announces CNY63m (~USD10m) Financing to Advance its Synthetic Lethal Platform and Pre-clinical Oncology Pipeline” (Feb 8, 2021).
Is Anticancer Bioscience still active?
Yes, Anticancer Bioscience is active; its latest activity on Parsers VC dates from Oct 18, 2021.